Evidence map›Paper›PMID 41331641›Full record

ReviewHereditary cancer in clinical practice2025

Skin cancer risk in hereditary mixed cancer syndromes.

Veera Nikkola, Anna Alakoski, Jukka-Pekka Mecklin, Toni T Seppälä, Jussi Nikkola, Kashmintan Schrader

Abstract readReview
In one paragraph

Review in Hereditary cancer in clinical practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Veera NikkolaHereditary Cancer Program, BC Cancer, 600 West 10th Avenue, Vancouver, Canada. veera.k.nikkola@gmail.com.
Anna AlakoskiDepartment of Dermatology, Tampere University Hospital, Tampere, Finland.
Jukka-Pekka MecklinDepartment of Education and Research, The Wellbeing Services County of Central Finland, Jyväskylä, Finland.
Toni T SeppäläFaculty of Medicine and Health Technology, Tampere University and Tays Cancer Centre, Tampere, Finland.
Jussi NikkolaFaculty of Medicine and Health Technology, Tampere University and Tays Cancer Centre, Tampere, Finland.
Kashmintan SchraderHereditary Cancer Program, BC Cancer, 600 West 10th Avenue, Vancouver, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hereditary cancer syndromes are genetic conditions that increase an individual's risk for multiple cancer types, often due to mutations that affect critical cellular processes such as DNA repair and cell cycle regulation. Skin cancers, including malignant melanoma (MM), basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and related precancerous lesions may be underrecognized in some hereditary cancer syndromes, as suggested by underlying biological mechanisms and their underreporting in studies. In this narrative review, we examine the skin cancer risks associated with the most prevalent hereditary cancer syndromes, including Li-Fraumeni syndrome (LFS), Lynch syndrome (LS), hereditary breast and ovarian cancer syndrome (HBOC), ATM-associated hereditary cancer syndrome, CHEK2-associated hereditary cancer syndrome, BRIP1-associated cancer predisposition, and hereditary leiomyomatosis and renal cell carcinoma (HLRCC). This review consolidates existing evidence and suggests that mixed cancer syndromes, especially LFS, LS, and HBOC but also pathogenic ATM and CHEK2 variants may predispose individuals to skin cancers, warranting tailored screening and preventive measures. On the basis of emerging evidence, we recommend dermatologic evaluation and individualized UV protection strategies for patients with reviewed hereditary cancer syndromes to reduce skin cancer risk and enhance early detection.

Indexed as

Genetic cancer predispositionGermline cancer susceptibility mutationsHereditary cancer syndromesHereditary skin cancerSkin cancer screening

Identifiers

PMID41331641
PMCPMC12777409

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.